Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity CommitmentsBusiness Wire • 08/23/23
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC MelanomaBusiness Wire • 08/22/23
Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023Business Wire • 08/21/23
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerBusiness Wire • 08/16/23
Bristol Myers Squibb stock extends bounce after announced $4 billion accelerated buyback agreementsMarket Watch • 08/10/23
Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity EffortsBusiness Wire • 08/10/23
Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase AgreementsBusiness Wire • 08/10/23
Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque PsoriasisBusiness Wire • 08/08/23
Compared to Estimates, Bristol Myers (BMY) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/27/23
Bristol Myers Squibb (BMY) Misses Q2 Earnings and Revenue EstimatesZacks Investment Research • 07/27/23